Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,400.09 -17.59 -0.12%
TOPIX 1,166.94 0.39 0.03%
HANG SENG 22,749.87 53.86 0.24%

Elan Announces Enrollment of First Patient in Phase 2 Study of ELND005 (Scyllo-inositol) for the Treatment of



  Elan Announces Enrollment of First Patient in Phase 2 Study of ELND005
  (Scyllo-inositol) for the Treatment of Agitation/Aggression in Patients with
  Alzheimer’s Disease

  * Approximately 90% of AD patients develop neuropsychiatric symptoms
  * Approximately 60% of AD patients develop agitation/aggression

Business Wire

DUBLIN -- November 27, 2012

Elan Corporation, plc (NYSE: ELN) today announced that it has enrolled the
first patient in a Phase 2 clinical trial of ELND005 (Study AG201) for the
treatment of agitation/aggression in patients with moderate to severe
Alzheimer’s disease (AD).

“Agitation/Aggression are common and distressing neuropsychiatric symptoms
(NPS) of AD. These symptoms are a leading cause of patients being placed in
nursing homes,” said Dr. Bruno Vellas, MD PhD, Chairman of Internal and
Geriatric Medicine at University Hospital Toulouse, France and Principal
Investigator of the European Alzheimer’s Disease Consortium. “Approximately
90% of AD patients develop NPS, and up to 60% develop agitation/aggression
over the course of their disease. With no approved therapies for
agitation/aggression in most countries, including the US, it is a major
treatment problem in AD. This trial is an important step in providing a
potential therapy to help manage these symptoms.”

“We believe ELND005 has opportunities in symptomatic neuropsychiatric
indications based on its potential beneficial effects coupled with a good
understanding of its safety profile from earlier clinical trials in AD.” said
Dr. Menghis Bairu, Chief Medical Officer and Head of Development at Elan.
“Symptomatic treatments are important in AD patient care, especially at the
advanced stages of disease. As patients advance in their AD, there is an
increase in both the prevalence and severity of agitation/aggression.”

Dr. Bairu added “From a development perspective, given the significant unmet
need in this patient group, we believe that potential beneficial effects on
agitation/aggression will provide a meaningful advance in patient management.”

About The Study

The objectives of Study AG201 are to evaluate the efficacy, safety and
tolerability of ELND005 over 12 weeks of treatment in patients with moderate
to severe AD, who are experiencing at least moderate levels of
agitation/aggression. The study is expected to enroll approximately 400
patients at multiple sites in the US, Canada and other selected regions. In
the Phase 2 AD Study (AD201), ELND005 appeared to decrease the emergence and
severity of specific NPS, an effect which seemed to correlate with drug
exposure for some symptoms. ELND005 also led to a sustained reduction of brain
Myo-inositol levels that are thought to play a role in phospho-inositol
signaling pathways and synaptic activity. More information on Study
ELND005-AG201 will be available at http://www.clinicaltrials.gov/.

About Neuropsychiatric Symptoms and Alzheimer’s Disease

It is currently estimated that approximately 5.4 million Americans and
approximately 7.2 million Europeans have AD and these numbers are expected to
rise to 16 million by 2050. AD is a progressive brain disorder that gradually
destroys a person’s memory and ability to learn, reason, make judgements,
communicate and carry out daily activities. Approximately 90% of AD patients
develop NPS, and up to 60% develop agitation/aggression over the course of
their disease. Agitation/aggression are among the most disruptive NPS in AD
and are associated with increased morbidity and caregiver burden.

About ELND005

ELND005 is an orally bioavailable small molecule that is being investigated by
Elan for multiple neuropsychiatric indications on the basis of its proposed
dual mechanism of action, which includes β-amyloid anti-aggregation and
regulation of brain myo-inositol levels. An extensive clinical program of
Phase 1 and Phase 2 studies have been completed with ELND005 to support
clinical development, including the recently published Phase 2 study
ELND005-AD201 in AD. ELND005 is also being studied as a maintenance treatment
of Bipolar Disease in an ongoing study (Study ELND005-BPD201). The ELND005
asset will remain with Elan following the demerger of the Prothena Business,
which is expected to complete by the end of 2012.

About Elan

Elan Corporation, plc (NYSE: ELN) is a neuroscience-based biotechnology
company committed to making a difference in the lives of patients and their
families by dedicating itself to bringing innovations in science to fill
significant unmet medical needs that continue to exist around the world. Elan
shares trade on the New York and Irish Stock Exchanges. For additional
information about the Company, please visit www.elan.com.

Safe Harbor/Forward-Looking Statements

This press release contains forward-looking statements regarding the
development of scyllo-inositol (ELND005). These statements are based on Elan's
current beliefs and expectations. ELND005 may not be successfully developed or
commercialized. Factors which could cause actual results to differ materially
from Elan's current expectations include the risks that clinical development
of ELND005 fails due to safety or efficacy issues, Elan fails to receive
regulatory approval to undertake additional clinical trials, the results from
Phase 1 and 2 clinical trials and preclinical testing of ELND005 are not
predictive of results to be obtained in later clinical trials, the patent with
respect to ELND005 may not provide substantial protection or commercial
benefit, the development and commercialization of competitive therapies, or
Elan encounters other delays or hurdles. Drug development and
commercialization involves a high degree of risk.

For more detailed information on the risks and uncertainties associated with
Elan's drug development and other activities, see the periodic and current
reports that Elan has filed with the Securities and Exchange Commission. Elan
assumes no obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise.

                                     ###

Contact:

Investor Relations:
Chris Burns
Ph: 1-800-252-3526
David Marshall
Ph: + 353-1-709-4444
or
Media Relations:
Emer Reynolds
Ph: + 353-1-709-4022
Jonathan Birt
Ph: + 44-751-559-7858
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement